Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TNKS1BP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TNKS1BP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TNKS1BP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TNKS1BP1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TNKS1BP1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TNKS1BP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007121410 | Prostate | BPH | cellular response to abiotic stimulus | 89/3107 | 331/18723 | 1.28e-06 | 2.23e-05 | 89 |
GO:010400410 | Prostate | BPH | cellular response to environmental stimulus | 89/3107 | 331/18723 | 1.28e-06 | 2.23e-05 | 89 |
GO:00062788 | Prostate | BPH | RNA-dependent DNA biosynthetic process | 29/3107 | 75/18723 | 3.92e-06 | 5.96e-05 | 29 |
GO:00714787 | Prostate | BPH | cellular response to radiation | 54/3107 | 186/18723 | 1.50e-05 | 1.92e-04 | 54 |
GO:00181078 | Prostate | BPH | peptidyl-threonine phosphorylation | 37/3107 | 116/18723 | 3.56e-05 | 3.90e-04 | 37 |
GO:00182108 | Prostate | BPH | peptidyl-threonine modification | 39/3107 | 125/18723 | 3.88e-05 | 4.20e-04 | 39 |
GO:00181059 | Prostate | BPH | peptidyl-serine phosphorylation | 79/3107 | 315/18723 | 7.09e-05 | 6.96e-04 | 79 |
GO:00718978 | Prostate | BPH | DNA biosynthetic process | 50/3107 | 180/18723 | 1.06e-04 | 9.73e-04 | 50 |
GO:00182097 | Prostate | BPH | peptidyl-serine modification | 82/3107 | 338/18723 | 1.73e-04 | 1.48e-03 | 82 |
GO:000931414 | Prostate | BPH | response to radiation | 105/3107 | 456/18723 | 2.07e-04 | 1.70e-03 | 105 |
GO:00102127 | Prostate | BPH | response to ionizing radiation | 42/3107 | 148/18723 | 2.20e-04 | 1.78e-03 | 42 |
GO:00467778 | Prostate | BPH | protein autophosphorylation | 52/3107 | 227/18723 | 8.26e-03 | 3.59e-02 | 52 |
GO:000072315 | Prostate | Tumor | telomere maintenance | 52/3246 | 131/18723 | 1.13e-09 | 5.43e-08 | 52 |
GO:000700415 | Prostate | Tumor | telomere maintenance via telomerase | 31/3246 | 69/18723 | 9.10e-08 | 2.45e-06 | 31 |
GO:001083315 | Prostate | Tumor | telomere maintenance via telomere lengthening | 34/3246 | 81/18723 | 1.69e-07 | 4.20e-06 | 34 |
GO:000627814 | Prostate | Tumor | RNA-dependent DNA biosynthetic process | 31/3246 | 75/18723 | 8.78e-07 | 1.73e-05 | 31 |
GO:007147916 | Prostate | Tumor | cellular response to ionizing radiation | 30/3246 | 72/18723 | 1.07e-06 | 2.05e-05 | 30 |
GO:007121415 | Prostate | Tumor | cellular response to abiotic stimulus | 92/3246 | 331/18723 | 1.25e-06 | 2.32e-05 | 92 |
GO:010400415 | Prostate | Tumor | cellular response to environmental stimulus | 92/3246 | 331/18723 | 1.25e-06 | 2.32e-05 | 92 |
GO:003220012 | Prostate | Tumor | telomere organization | 52/3246 | 159/18723 | 1.73e-06 | 3.05e-05 | 52 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TNKS1BP1 | SNV | Missense_Mutation | | c.1729N>T | p.Gly577Cys | p.G577C | Q9C0C2 | protein_coding | deleterious(0.04) | benign(0.035) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
TNKS1BP1 | SNV | Missense_Mutation | | c.1642C>G | p.Pro548Ala | p.P548A | Q9C0C2 | protein_coding | tolerated(0.1) | benign(0.04) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
TNKS1BP1 | SNV | Missense_Mutation | novel | c.2095N>C | p.Ala699Pro | p.A699P | Q9C0C2 | protein_coding | deleterious(0.03) | possibly_damaging(0.469) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
TNKS1BP1 | SNV | Missense_Mutation | rs763983688 | c.196N>T | p.Arg66Trp | p.R66W | Q9C0C2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
TNKS1BP1 | SNV | Missense_Mutation | | c.88G>A | p.Glu30Lys | p.E30K | Q9C0C2 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TNKS1BP1 | SNV | Missense_Mutation | novel | c.540N>A | p.Asp180Glu | p.D180E | Q9C0C2 | protein_coding | deleterious(0.04) | benign(0.323) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNKS1BP1 | SNV | Missense_Mutation | novel | c.41C>T | p.Ser14Phe | p.S14F | Q9C0C2 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-BH-A1EO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TNKS1BP1 | SNV | Missense_Mutation | rs774760397 | c.4129N>A | p.Gly1377Ser | p.G1377S | Q9C0C2 | protein_coding | tolerated(0.1) | benign(0.338) | TCGA-E9-A249-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
TNKS1BP1 | insertion | Frame_Shift_Ins | novel | c.5034_5035insAAAGTTTGCATTCTGGACCTTTGCCGTCTGCCTCCTAGGT | p.Gln1679LysfsTer69 | p.Q1679Kfs*69 | Q9C0C2 | protein_coding | | | TCGA-A7-A0D9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
TNKS1BP1 | insertion | Frame_Shift_Ins | novel | c.5149_5150insGGCACTCACCACCACACCTGGCTAATTTTTGTATTTTTAAT | p.Asn1717ArgfsTer20 | p.N1717Rfs*20 | Q9C0C2 | protein_coding | | | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |